Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: biogen.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/14/2024 | $305.00 → $300.00 | Buy | Needham |
2/14/2024 | $315.00 → $240.00 | Overweight → Equal Weight | Wells Fargo |
1/24/2024 | $311.00 → $276.00 | Buy → Neutral | UBS |
12/20/2023 | $311.00 | Overweight | Cantor Fitzgerald |
12/7/2023 | $283.00 | Mkt Perform → Outperform | Raymond James |
9/6/2023 | $360.00 | Buy | HSBC Securities |
7/27/2023 | $327.00 | Sector Outperform | Scotiabank |
7/24/2023 | $346.00 → $335.00 | Buy | UBS |
5/1/2023 | $270.00 → $350.00 | Neutral → Buy | Guggenheim |
4/17/2023 | $280.00 → $346.00 | Neutral → Overweight | Piper Sandler |
Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical improvements were observed among key secondary endpoints measuring disease activity and flares.UCB and Biogen are advancing dapirolizumab pegol with the objective to address the substantial unmet medical need for people living with SLE, where there are limited treatment options.SLE is a chronic, debilitating autoimmune disease that affects multiple organ systems and disproportionately affects women. BRUSSELS and CAMBRIDGE, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ:BIIB) today announced positi
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- The Biogen Inc. (NASDAQ:BIIB) Board of Directors (the "Board") today announced the appointments of two new independent directors, Lloyd B. Minor, M.D., effective October 1, 2024, and Sir Menelas (Mene) Pangalos, Ph.D., effective January 1, 2025. Dr. Minor is currently the Dean of the Stanford University School of Medicine and Vice President for Medical Affairs at Stanford University, and Prof Sir Pangalos was most recently Executive Vice President of Biopharmaceuticals R&D at AstraZeneca until his retirement in April 2024. "We welcome Lloyd and Mene to our Board as they add significant experience and proven track records in leading R&D
Positive study demonstrates the potential for investigational higher dose nusinersen regimen to advance the treatment of SMA; Biogen plans to submit for regulatory approval of this investigational dose regimenHigher dose nusinersen regimen showed statistically significant improvement compared to a prespecified matched sham control groupAmong key measures of clinical efficacy, higher dose regimen showed positive trends compared to the approved dosing regimen CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced positive, topline data from the pivotal cohort (Part B) of the Phase 2/3 DEVOTE study evaluating the safety and efficacy of a higher dose re
FOR GLOBAL MEDIA AND JOURNALISTS OUTSIDE THE EMEA REGION In Great Britain, lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease (AD) in adult patients that are apolipoprotein E ε4 (ApoE ε4)* heterozygotes or non-carriers1 Great Britain becomes the first country in Europe to authorize the medicine, which targets an underlying cause of AD1 TOKYO and CAMBRIDGE, Mass., Aug. 22, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ", Biogen", ))) announced today that the humanized amyloid-be
Alcyone's ThecaFlex is an implantable medical device under investigation for routine subcutaneous administration of therapeutics to the cerebrospinal fluid (CSF).The first stage of the pivotal IDE PIERRE trial has been completed.10 spinal muscular atrophy (SMA) patients have undergone ThecaFlex implantation and have received nusinersen through the device.No device-related adverse events, including infections, were observed in the 30 days after implantation.FDA has agreed to an additional 80-SMA patient, 30-center, enrollment after review of the clinical data by Data Monitoring Safety Committee of first 10 SMA patients implanted.LOWELL, Mass., July 31, 2024 /PRNewswire/ -- Alcyone Therapeutic
51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau / Low Tau Patient Group Clinical Data and Biomarkers Show Alzheimer's Disease Does Not Stop Progressing After Plaque Clearance. Lecanemab's Dual Action Supports Neuronal Function by Clearing Highly Toxic Protofibrils that Continue to Cause Neuronal Injury and Death After Rapid Plaque Clearance Lecanemab Slows Tau Spread Across All Brain Regions PHILADELPHIA, July 30, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Headquarters: Cambridge, Massachusetts, United States, CEO: Christopher
- 51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau / Low Tau Patient Group - Clinical Data and Biomarkers Show Alzheimer's Disease Does Not Stop Progressing After Plaque Clearance. Lecanemab's Dual Action Supports Neuronal Function by Clearing Highly Toxic Protofibrils that Continue to Cause Neuronal Injury and Death After Rapid Plaque Clearance - Lecanemab Slows Tau Spread Across All Brain Regions PHILADELPHIA, July 30, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Headquarters: Cambridge, Massachusetts, United States, CEO: Christopher A
The collaboration aims to identify and develop accessible, minimally invasive blood-based biomarkers specific for tau pathology in the brainThese tools have the potential to be used to stratify patients or monitor treatment response for a new generation of future therapies impacting tau pathology in Alzheimer's disease CAMBRIDGE, Mass. and BREA, Calif. and TOKYO, July 30, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB), Beckman Coulter, Inc. and Fujirebio announced a collaboration to potentially identify and develop blood-based biomarkers for tau pathology in the brain and to potentially clinically advance and potentially commercialize new tests for tau pathology in Alzheimer's disease
TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen"))) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Approval (MAA) for the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab as treatment for early AD (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD).1 "We are extremely disappointed by the CHMP's negative opinion
- SAGE-324 (BIIB124) did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor - No statistically significant differences were demonstrated between any dose of SAGE-324 and placebo in the change from baseline for the primary endpoint Sage Therapeutics, Inc. (NASDAQ:SAGE) and Biogen Inc. (NASDAQ:BIIB) announced topline results from the Phase 2 KINETIC 2 dose-range study of the oral investigational drug SAGE-324 (BIIB124) as a potential treatment in essential tremor (ET). The KINETIC 2 Study did not demonstrate a statistically significant dose-response relationship in change from baseline to Day 91 based on the
4 - BIOGEN INC. (0000875045) (Issuer)
Needham reiterated coverage of Biogen with a rating of Buy and set a new price target of $300.00 from $305.00 previously
Wells Fargo downgraded Biogen from Overweight to Equal Weight and set a new price target of $240.00 from $315.00 previously
UBS downgraded Biogen from Buy to Neutral and set a new price target of $276.00 from $311.00 previously
Cantor Fitzgerald resumed coverage of Biogen with a rating of Overweight and set a new price target of $311.00
Raymond James upgraded Biogen from Mkt Perform to Outperform and set a new price target of $283.00
HSBC Securities initiated coverage of Biogen with a rating of Buy and set a new price target of $360.00
Scotiabank initiated coverage of Biogen with a rating of Sector Outperform and set a new price target of $327.00
UBS reiterated coverage of Biogen with a rating of Buy and set a new price target of $335.00 from $346.00 previously
Guggenheim upgraded Biogen from Neutral to Buy and set a new price target of $350.00 from $270.00 previously
Piper Sandler upgraded Biogen from Neutral to Overweight and set a new price target of $346.00 from $280.00 previously
8-K - BIOGEN INC. (0000875045) (Filer)
8-K - BIOGEN INC. (0000875045) (Filer)
10-Q - BIOGEN INC. (0000875045) (Filer)
8-K - BIOGEN INC. (0000875045) (Filer)
8-K - BIOGEN INC. (0000875045) (Filer)
S-8 - BIOGEN INC. (0000875045) (Filer)
ARS - BIOGEN INC. (0000875045) (Filer)
DEFA14A - BIOGEN INC. (0000875045) (Filer)
DEF 14A - BIOGEN INC. (0000875045) (Filer)
10-Q - BIOGEN INC. (0000875045) (Filer)
Sage Therapeutics Inc. (NASDAQ:SAGE) and Biogen Inc. (NASDAQ:BIIB) announced results Wednesday from the Phase 2 KINETIC 2 dose-range study of SAGE-324 (BIIB124) as a potential treatment for essential tremor (ET). The KINETIC 2 Study did not demonstrate a statistically significant dose-response relationship in change from baseline to Day 91 based on the primary endpoint, The Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale (PS) Item 4 (upper limb) total score. TETRAS is used to quantify the severity of tremors and their impact on daily living activities. Also Read: Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson’s Dat
Ionis Pharmaceuticals Inc (NASDAQ:IONS) released results Monday from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome (AS). AS is a rare neurodevelopmental disorder caused by a loss of function in the maternal UBE3A gene. It affects an estimated 1 in 21,000 people worldwide. The data demonstrated consistent and encouraging clinical improvement on assessing all functional domains, including communication, cognition, and motor function measures. Also Read: Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile. Overall, 97% of peop
Sen. Bernie Sanders (I-Vt.) recently expressed his concerns about the high cost of medical care in the United States, highlighting the financial burden it places on patients. What Happened: On Monday, Sanders took to X to voice his concerns about the high cost of healthcare in the United States. He pointed out that the U.S. is the only major country where an emergency hospital visit can lead to financial ruin for patients. He stated, “Getting sick in America should not mean going bankrupt, losing your home, car, or life savings.” Sanders shared a video featuring various medical professionals who shared stories about the high cost of medical care in the U.S. We are the only major co
In the latest quarter, 19 analysts provided ratings for Biogen (NASDAQ:BIIB), showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 8 7 4 0 0 Last 30D 0 1 0 0 0 1M Ago 1 2 0 0 0 2M Ago 3 2 0 0 0 3M Ago 4 2 4 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $285.32, a high estimate of $342.00, and a low estimate of $200.00. A decline of 2.16% from the prior average price target
Piper Sandler analyst Christopher Raymond maintains Biogen (NASDAQ:BIIB) with a Overweight and lowers the price target from $335 to $313.
On Tuesday, the FDA approved Eli Lilly and Co’s (NYSE:LLY) Kisunla (donanemab) once-monthly injection for IV infusion) for adults with early symptomatic Alzheimer’s disease. Once-monthly, Kisunla is the first and only amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed, which can result in lower treatment costs and fewer infusions. Also Read: Why Is Eli Lilly Stock Trading Higher Premarket Tuesday? Amyloid is a protein produced naturally in the body that can clump together to create amyloid plaques. The excessive buildup of amyloid plaques in the brain may lead to memory and thinking issues associated with Alzheimer’s disease.
Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $294 price target.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ", Biogen", ))))) announced today that the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI®" (brand name in China: "乐意保®", generic name: lecanemab) has been launched in China. LEQEMBI received approval in January 2024 as a treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia. China is the third country to launch LEQEMBI following the United States and Japan. LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils*), as well as inso
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form
Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)
Submission status for BIOGEN INC's drug VUMERITY (SUPPL-15) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211855, Application Classification: Labeling
Submission status for BIOGEN INC's drug TECFIDERA (SUPPL-31) with active ingredient DIMETHYL FUMARATE has changed to 'Approval' on 03/12/2024. Application Category: NDA, Application Number: 204063, Application Classification: Labeling
Submission status for BIOGEN INC's drug VUMERITY (SUPPL-16) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 211855, Application Classification: Labeling
Submission status for BIOGEN INC's drug TECFIDERA (SUPPL-32) with active ingredient DIMETHYL FUMARATE has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 204063, Application Classification: Labeling
Submission status for BIOGEN INC's drug ADUHELM (SUPPL-11) with active ingredient ADUCANUMAB-AVWA has changed to 'Approval' on 08/30/2023. Application Category: BLA, Application Number: 761178, Application Classification:
Submission status for BIOGEN INC's drug VUMERITY (SUPPL-9) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 02/10/2023. Application Category: NDA, Application Number: 211855, Application Classification: Efficacy
Submission status for BIOGEN INC's drug TECFIDERA (SUPPL-29) with active ingredient DIMETHYL FUMARATE has changed to 'Approval' on 02/10/2023. Application Category: NDA, Application Number: 204063, Application Classification: Efficacy
Submission status for BIOGEN INC's drug ADUHELM (SUPPL-7) with active ingredient ADUCANUMAB-AVWA has changed to 'Approval' on 02/08/2023. Application Category: BLA, Application Number: 761178, Application Classification:
SC 13G/A - BIOGEN INC. (0000875045) (Subject)
SC 13G/A - BIOGEN INC. (0000875045) (Subject)
SC 13G/A - BIOGEN INC. (0000875045) (Subject)
SC 13G/A - BIOGEN INC. (0000875045) (Subject)
SC 13G/A - BIOGEN INC. (0000875045) (Subject)
SC 13G/A - BIOGEN INC. (0000875045) (Subject)
SC 13G/A - BIOGEN INC. (0000875045) (Subject)
SC 13G/A - BIOGEN INC. (0000875045) (Subject)
SC 13G/A - BIOGEN INC. (0000875045) (Subject)
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs). "We are very excited about the addition of felzartamab into our pipeline, further strengthening our presence in immunology with a promising late-stage therapeutic candidate being studied in multiple indications," said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. "With the transaction now complete, we will begin working together with our colleagues from HI-Bio on plans to advance felzart
Reata acquisition bolsters Biogen's rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment for Friedreich's ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (NASDAQ:RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of the transaction, Biogen has now acquired SKYCLARYS® (omaveloxolone), as well as other clinical and preclinical pipeline programs. SKYCLARYS®, Reata Pharmaceuticals' lead asset, was approved for the treatment of
SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich's ataxia Proposed acquisition represents meaningful step forward in Biogen's strategy for sustainable growth, adding a highly complementary innovative product in an area of high unmet medical needExpected to be significantly accretive to Biogen's Non-GAAP diluted EPS beginning in 2025Biogen to host investor conference call today at 9:00 a.m. ET. CAMBRIDGE, Mass. and PLANO, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Reata Pharmaceuticals, Inc. (NASDAQ:RETA) today announced the companies have entered into a definitive agreement under which Biogen has agreed to a
Zuranolone 50 mg demonstrated a statistically significant and clinically meaningful improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints Zuranolone 50 mg was generally well-tolerated and demonstrated a safety profile consistent with prior studies Postpartum depression is one of the most common medical complications during and after pregnancy impacting approximately 1 in 8 women annually in the U.S. Sage Therapeutics to host conference call today at 8:00 am ET Sage Therapeutics, Inc. (NASDAQ:SAGE) and Biogen Inc. (NASDAQ:BIIB) today announced that the Phase 3 SKYLARK Study of zuranolone, an investigational oral drug being
At the Day 3 primary endpoint, zuranolone 50 mg co-initiated with a standard of care antidepressant showed a statistically significant reduction in depressive symptoms Key secondary endpoint demonstrates zuranolone co-initiated with an antidepressant was statistically significant in reducing depressive symptoms compared to an antidepressant co-initiated with placebo over the 2-week treatment period Zuranolone 50 mg co-initiated with a standard of care antidepressant was generally well-tolerated with most TEAEs reported as mild or moderate and no new safety signals identified Sage Therapeutics to host conference call today at 8:00 a.m. ET Sage Therapeutics, Inc. (NASDAQ:SAGE), and Biogen
Improvement in measurements of overall quality of life, functioning and general well-being achieved at Day 15 and sustained at Day 42 Consistent and differentiated safety and tolerability profile seen across clinical programs Sage to host conference call on October 4, 2021 at 8:00am ET Sage Therapeutics, Inc. (NASDAQ:SAGE) and Biogen Inc. (NASDAQ:BIIB) today announced new data from the LANDSCAPE and NEST clinical development programs evaluating the efficacy and safety of zuranolone for the treatment of major depressive disorder (MDD) and postpartum depression (PPD) presented at the 34th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 2-5, 2021. Presentat
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- The Biogen Inc. (NASDAQ:BIIB) Board of Directors (the "Board") today announced the appointments of two new independent directors, Lloyd B. Minor, M.D., effective October 1, 2024, and Sir Menelas (Mene) Pangalos, Ph.D., effective January 1, 2025. Dr. Minor is currently the Dean of the Stanford University School of Medicine and Vice President for Medical Affairs at Stanford University, and Prof Sir Pangalos was most recently Executive Vice President of Biopharmaceuticals R&D at AstraZeneca until his retirement in April 2024. "We welcome Lloyd and Mene to our Board as they add significant experience and proven track records in leading R&D
CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced the appointment of Monish Patolawala, currently President and Chief Financial Officer of 3M Company ("3M"), to the Company's Board of Directors (the "Board"), effective January 1, 2024. As an accomplished financial executive, Mr. Patolawala is qualified as an Audit Committee financial expert and may be asked to serve as a member of the Board's Audit Committee. "We are pleased to welcome Monish to the Board as the Company is advancing on its next chapter," said Caroline Dorsa, Chair of the Biogen Board of Directors. "Monish's deep financial expertise and diversified management experience at leadin
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced the appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research effective 2 October 2023. Dr. Grogan will be a member of Biogen's Executive Committee reporting to Christopher A. Viehbacher, President and Chief Executive Officer. "Dr. Grogan is a pioneering scientist whose groundbreaking discoveries at Genentech helped pave the way for development of targeted autoimmune and oncology therapies. I believe Jane will be a strong asset to Biogen as we seek to bring a greater number of innovative medicines to market faster and more effectively," said Mr. Viehbacher. "Together with Dr. Pr
CAMBRIDGE, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced the appointment of Adam Keeney, Ph.D., as Executive Vice President, Head of Corporate Development effective 17 April 2023. Dr. Keeney will be a member of Biogen's Executive Committee reporting to Christopher A. Viehbacher, President and Chief Executive Officer. "We welcome Adam Keeney to our executive leadership team in this important role at this pivotal time for Biogen. Adam brings considerable experience in biopharmaceutical strategy and business development with a solid track record of value-creating deals throughout his career," said Mr. Viehbacher. "As we are working to put Biogen on a sus
CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced the appointment of Chuck Triano as Senior Vice President, Head of Investor Relations effective 10 April 2023. Mr. Triano will report to Michael McDonnell, Executive Vice President and Chief Financial Officer. "Chuck will bring invaluable industry insights and a strong network of relationships to Biogen, and I'm pleased to welcome him to our leadership team," said Michael McDonnell, Executive Vice President and Chief Financial Officer. "His wealth of experience collaborating with company leaders through periods of strong growth and transition will enhance our continuous efforts to inform invest
CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced today that Alfred "Al" W. Sandrock, Jr., M.D., Ph.D., Head of Research & Development, will retire from the Company effective December 31, 2021. A 23-year veteran of Biogen, Dr. Sandrock, 64, led the development of many of the Company's most important and transformational therapies in neurological diseases, including Tysabri® (natalizumab), Tecfidera® (dimethyl fumarate), Spinraza® (nusinersen), Plegridy® (peginterferon beta-1a) and Aduhelm™ (aducanumab-avwa). Dr. Sandrock served on Biogen's Executive Committee since 2015, as Head of Research & Development since October 2019, and as Chief Medical Officer
BOSTON--(BUSINESS WIRE)--Atalanta Therapeutics, a biotechnology company pioneering new treatment options for neurodegenerative diseases, launched today with a Series A financing exclusively by F-Prime Capital. Additionally, Atalanta announced strategic collaborations with Biogen (Nasdaq: BIIB) and Genentech, a member of the Roche Group. The total committed funding at launch with the upfront payments from the two partnerships and Series A financing is $110 million. Atalanta was founded to address a central limitation for today’s RNAi therapeutics: the difficulty of achieving distribution throughout the brain and spinal cord. Atalanta’s proprietary technology, called branched siRNA